공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

부갑상선 기능 저하증 : 파이프라인 리뷰

Hypoparathyroidism (Hormonal Disorders) - Drugs in Development, 2021

리서치사 Global Markets Direct
발행일 2021년 09월 상품 코드 200460
페이지 정보 영문 66 Pages
가격
US $ 2,000 ₩ 2,395,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,790,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,185,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


부갑상선 기능 저하증 : 파이프라인 리뷰 Hypoparathyroidism (Hormonal Disorders) - Drugs in Development, 2021
발행일 : 2021년 09월 페이지 정보 : 영문 66 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

부갑상선 기능 저하증은 부갑상선의 기능 감퇴에 의해 부갑상선 호르몬 생산량이 감소하여 발생하며, 혈중 칼슘 농도의 저하, 근육의 경련 및 수축(불수의 근육 수축), 기타 증상을 수반합니다. 유전이 원인인 경우도 있으나 갑상선 또는 부갑상선 수술 후 발생하거나, 드물기는 하지만 면역계 장애가 원인인 경우도 있습니다. 치료에는 인공 호르몬, 칼슘제 및 비타민 투여 등을 시행합니다.

부갑상선 기능 저하증 치료제 개발 상황에 대해 조사분석했으며, 파이프라인 제품의 개요, 임상시험 단계별 제품의 개요, 주요 기업의 개요, 약제 개요, 파이프라인 제품의 최신 동향, 최신 뉴스와 프레스 릴리스 등에 관한 정보를 정리하여 전해드립니다.

목차

서론

부갑상선 기능 저하증 개요

치료제 개발

  • 파이프라인 제품 : 개요
  • 기업별 파이프라인
  • 기업에서 개발중인 제품

치료제 평가

  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 유형별

치료제 개발에 참여하고 있는 기업

  • Ascendis Pharma A/S
  • Chugai Pharmaceutical Co Ltd
  • Eli Lilly and Company
  • Entera Bio Ltd
  • Pharis Biotec GmbH
  • Shire Plc

약제 개요

휴지중인 프로젝트

제품 개발 마일스톤

  • 주목 뉴스와 프레스 릴리스

부록

도표

KSA 17.06.27

List of Tables

List of Tables

  • Number of Products under Development for Hypoparathyroidism, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Hypoparathyroidism - Pipeline by Aerami Therapeutics Inc, 2021
  • Hypoparathyroidism - Pipeline by Aeterna Zentaris Inc, 2021
  • Hypoparathyroidism - Pipeline by Amolyt Pharma, 2021
  • Hypoparathyroidism - Pipeline by Ascendis Pharma AS, 2021
  • Hypoparathyroidism - Pipeline by BridgeBio Pharma Inc, 2021
  • Hypoparathyroidism - Pipeline by Chugai Pharmaceutical Co Ltd, 2021
  • Hypoparathyroidism - Pipeline by Eli Lilly and Co, 2021
  • Hypoparathyroidism - Pipeline by Entera Bio Ltd, 2021
  • Hypoparathyroidism - Pipeline by Extend Biosciences Inc, 2021
  • Hypoparathyroidism - Pipeline by GC Pharma, 2021
  • Hypoparathyroidism - Pipeline by ProLynx LLC, 2021
  • Hypoparathyroidism - Dormant Projects, 2021

List of Figures

List of Figures

  • Number of Products under Development for Hypoparathyroidism, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Targets, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypoparathyroidism - Drugs In Development, 2021, provides an overview of the Hypoparathyroidism (Hormonal Disorders) pipeline landscape.Hypoparathyroidism is decreased function of the parathyroid glands with underproduction of parathyroid hormone. This leads to low levels of calcium in the blood, often causing cramping and twitching of muscles (involuntary muscle contraction), and several other symptoms. The condition can be inherited, but it is also encountered after thyroid or parathyroid gland surgery, and it can be caused by immune system-related damage as well as a number of rarer causes. The treatment includes artificial form of the hormone that can be administered as replacement, calcium replacement or vitamin.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypoparathyroidism - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Hypoparathyroidism (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Hypoparathyroidism (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypoparathyroidism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 5 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Hypoparathyroidism (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hypoparathyroidism (Hormonal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hypoparathyroidism (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hypoparathyroidism (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hypoparathyroidism (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hypoparathyroidism (Hormonal Disorders)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hypoparathyroidism (Hormonal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hypoparathyroidism (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Hypoparathyroidism - Overview
  • Hypoparathyroidism - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Hypoparathyroidism - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Hypoparathyroidism - Companies Involved in Therapeutics Development
  • Aerami Therapeutics Inc
  • Aeterna Zentaris Inc
  • Amolyt Pharma
  • Ascendis Pharma AS
  • BridgeBio Pharma Inc
  • Chugai Pharmaceutical Co Ltd
  • Eli Lilly and Co
  • Entera Bio Ltd
  • Extend Biosciences Inc
  • GC Pharma
  • ProLynx LLC
  • Hypoparathyroidism - Drug Profiles
  • ACP-014 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Aerami-701 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AEZS-150 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AZP-3601 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CLTX-305 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • encaleret - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EXT-608 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LY-6272K - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PCO-371 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PLX-134 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Stem cell Therapy for Hypoparathyroidism - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • teriparatide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Hypoparathyroidism - Dormant Projects
  • Hypoparathyroidism - Product Development Milestones
  • Featured News & Press Releases
  • Sep 10, 2021: Amolyt Pharma to host key opinion leader webinar and discuss results of phase I clinical trial of AZP-3601 on Friday, October 1st at 10:00am ET
  • Jul 06, 2021: Ascendis Pharma announces target enrollment achieved in the Phase 3 PaTHway trial of TransCon PTH (palopegteriparatide) in adults with hypoparathyroidism (HP) and provides a comprehensive global clinical program update
  • Jun 03, 2021: The first hormone replacement therapy for hypoparathyroidism in China obtains IND approval for Phase III clinical trial
  • Jun 01, 2021: BridgeBio Pharma receives FDA Fast Track designation for encaleret for the treatment of autosomal dominant hypocalcemia type 1
  • May 18, 2021: Amolyt Pharma present new phase 1 data on AZP-3601 its parathyroid hormone analog for hypoparathyroidism, at upcoming scientific conferences
  • May 12, 2021: Ascendis Pharma announces expansion of global clinical reach for TransCon PTH with filing of the clinical trial notification for phase 3 clinical trial in adults with hypoparathyroidism in Japan
  • May 10, 2021: Ascendis Pharma announces preliminary 58-week results from open-label extension of phase 2 PaTH forward trial of TransCon PTH in adult hypoparathyroidism demonstrated durable benefit and a well-tolerated safety profile
  • May 06, 2021: Aeterna Zentaris announces the selection of a development candidate in the DC-PTH program for the potential treatment of primary hypoparathyroidism
  • May 06, 2021: Ascendis Pharma announces presentations for TransCon PTH at upcoming medical conferences
  • Mar 23, 2021: Ascendis Pharma presents 6-month open-label extension data from phase 2 path forward trial of TransCon PTH in adult Hypoparathyroidism at ENDO 2021
  • Mar 22, 2021: Amolyt Pharma presents first clinical data for AZP-3601, its parathyroid hormone analog for hypoparathyroidism, at the Endocrine Society's Virtual Annual Meeting (ENDO 2021)
  • Mar 20, 2021: BridgeBio Pharma announces proof-of-concept data of Encaleret in ADH1 at the Endocrine Society's 2021 Annual Meeting
  • Mar 16, 2021: Amolyt pharma to present preliminary phase 1 data on AZP-3601 at ENDO 2021
  • Feb 25, 2021: Entera Bio announces publication of phase 2 hypoparathyroidism study in the Journal of Bone and Mineral Research
  • Jan 06, 2021: Amolyt Pharma receives Orphan Drug Designation for AZP-3601 for the potential treatment of hypoparathyroidism
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q